Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (11834)	11/28/1997 11:24:00 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 32384

Henry, I agree with you. I think the deal is done and if not, LGND needs new lawyers. I find it hard to believe that a news release involving the likes of LLY and others would have been issued without SEC approval. OFF Topic: What do you think about the ENMD news and what is your take on Eisinger's articles about OSIP and NXTR?

To: Henry Niman who wrote (11834)	11/29/1997 2:43:00 AM
From: Andrew H	Respond to of 32384

Henry and others--reposting this from the VD thread. Has anyone seen the article?? Was there any other mention of LGND's drugs? >>The November 7 Issue of Science is entitled " Frontiers In Cancer Research" An article at page 1041 is called Systems for idnetifying new Drugs Are Often Faulty. Quoting from the article " "Indeed since formal screening began in 1955, many thousands of drugs have shown activity either cell or animal models, only 39 that are used extensively for chemotherapy, as opposed to supportive care, have won approval form the FDA. " The fundemental problem with drug discovery for cancer is that the model systems are not predictive at all", says Alan Oliff, executive director for cancer research at Merck Research Laboratories in West Point, Pennsylvania." Also of interest in the issue is an article entitled " Recent Advances In Chemoprevention Of Cancer" at page 1073. Retiniods such as Ligand's Targretin are prominently mentioned as a preventative therapy for breast cancer. V1<<

To: Henry Niman who wrote (11834)	11/29/1997 3:09:00 AM
From: Andrew H	Respond to of 32384

More from V1 on the VD thread. What do you think Henry? >>However, it may be possible to do secondary prevention trials on those at extremely high risk for a tumor such as those who have had a tumor surgically removed. There are a number of such trials under way and the initial results are quite encouraging. If these trials are successful and Retiniods continue to show a very mild side effect profile the future could include those at high risk for certain cancers taking retiniod therapy like vitamins as a preventative. This is one of the reasons I continue to be so excited about LGNDs long term prospects. We should ask Henry what he thinks.<<